First Trust Nasdaq Pharmaceuticals ETF
FTXH
22 hedge funds and large institutions have $7.55M invested in First Trust Nasdaq Pharmaceuticals ETF in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.
3.76% more ownership
Funds ownership: 39.73% → 43.5% (+3.8%)
7% less capital invested
Capital invested by funds: $8.12M → $7.55M (-$573K)
8% less funds holding
Funds holding: 24 → 22 (-2)
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
+$611K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$549K |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$401K |
| 4 |
Morgan Stanley
New York
|
+$170K |
| 5 |
NB
NBT Bank
Norwich,
New York
|
+$21.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$536K |
| 2 |
Goldman Sachs
New York
|
-$534K |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
-$530K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$346K |
| 5 |
SPIA
Steward Partners Investment Advisory
New York
|
-$272K |
FTXH Hedge Fund Activity: Q3 2024 in Review
22 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in First Trust Nasdaq Pharmaceuticals ETF (FTXH) for Q3 2024, worth a combined $7.55M — down 7.1% from $8.12M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of FTXH and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was NewEdge Advisors, opening a new position worth an estimated $611K. The largest seller was Royal Bank of Canada, cutting an estimated $536K.
- 22 institutional investors held First Trust Nasdaq Pharmaceuticals ETF (FTXH) as of Q3 2024, down from 24 in Q2 2024.
- Funds reported $7.55M of First Trust Nasdaq Pharmaceuticals ETF stock for Q3 2024, down 7.1% quarter-over-quarter.
- 4 funds opened new First Trust Nasdaq Pharmaceuticals ETF positions in Q3 2024 and 6 closed out, a net change of -2 holders.
- The largest First Trust Nasdaq Pharmaceuticals ETF buyer in Q3 2024 was NewEdge Advisors, an estimated $611K added.
- The largest First Trust Nasdaq Pharmaceuticals ETF seller in Q3 2024 was Royal Bank of Canada, an estimated $536K sold.
Based on aggregated 13F filings for Q3 2024.